Effect of melatonin in epithelial mesenchymal transition markers and invasive properties of breast cancer stem cells of canine and human cell lines

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Do Nascimento Gonçalves, Naiane ^a   Colombo, Jucimara ^a   Lopes, Juliana Ramos ^b   Gelaleti, Gabriela Bottaro ^b   Moschetta, Marina Gobbe ^a   Sonehara, Nathália Martins ^a   Hellmén, Eva ^c   De Freitas Zanon, Caroline ^b   Oliani, Sônia Maria ^b   Pires De Campos Zuccari, Debora Aparecida ^a,b  

^a FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CD24 ANTIGEN; HERMES ANTIGEN; MELATONIN; NERVE CELL ADHESION MOLECULE; OCTAMER TRANSCRIPTION FACTOR 4; TUMOR MARKER; UVOMORULIN; VIMENTIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL CULTURE; CANCER STEM CELL; CELL ASSAY; CELL INVASION; CELL MIGRATION; CELL POPULATION; CELL VIABILITY; CMT U229 CANCER CELL LINE; COLORIMETRY; CONTROLLED STUDY; DENSITOMETRY; DOG BREED; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MCF 7 CELL LINE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; BREAST; BREAST NEOPLASMS; CELL MOTION; CELL SURVIVAL; DOG; DRUG EFFECTS; FEMALE; MCF-7 CELL LINE; PATHOLOGY; PREVENTION AND CONTROL; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DOGS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MCF-7 CELLS; MELATONIN; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS;

EID: 84962572098     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150407     Document Type: Article

References (78)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. doi: 10.3322/caac.20107 PMID: 21296855.
2. Manuali E, De Giuseppe A, Feliziani F, Forti K, Casciari C, Marchesi MC, et al. CA 15-3 cell lines and tissue expression in canine mammary cancer and the correlation between serum levels and tumour histological grade. BMC Vet Res. 2012; 8:86. doi: 10.1186/1746-6148-8-86 PMID: 22726603; PubMed Central PMCID: PMCPMC3412725.
3. Zuccari DAPC, Pavam MV, Terzian ACB, Pereira RS, Ruiz CM, Andrade JC. Immunohistochemical evaluation of e-cadherin, Ki-67 and PCNA in canine mammary neoplasias: Correlation of prognostic factors and clinical outcome. 2008. p. 207-15.
4. Ma Y, Hao X, Zhang S, Zhang J. The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells. Breast Cancer Res Treat. 2012; 133(2):473-85. doi: 10.1007/s10549-011-1774-x PMID: 21947651.
5. Chen K, Huang YH, Chen JL. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin. 2013; 34(6):732-40. doi: 10.1038/aps.2013.27 PMID: 23685952; PubMed Central PMCID: PMCPMC3674516.
6. Luo M, Clouthier SG, Deol Y, Liu S, Nagrath S, Azizi E, et al. Breast cancer stem cells: current advances and clinical implications. Methods Mol Biol. 2015; 1293:1-49. doi: 10.1007/978-1-4939-2519-3 1 PMID: 26040679.
7. Mitra A, Mishra L, Li S. EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget. 2015; 6(13):10697-711. PMID: 25986923.
8. Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH. Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol. 2013;Chapter 14:Unit 14.25. doi: 10.1002/0471141755.ph1425s61 PMID: 23744710; PubMed Central PMCID: PMCPMC3733496.
9. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumor-igenic breast cancer cells. Proc Natl Acad Sci USA. 2003; 100(7):3983-8. doi: 10.1073/pnas. 0530291100 PMID: 12629218; PubMed Central PMCID: PMCPMC153034.
10. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005; 65 (13):5506-11. doi: 10.1158/0008-5472.CAN-05-0626 PMID: 15994920.
11. Cariati M, Naderi A, Brown JP, Smalley MJ, Pinder SE, Caldas C, et al. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer. 2008; 122(2):298-304. doi: 10.1002/ijc.23103 PMID: 17935134.
12. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003; 17(10):1253-70. doi: 10.1101/gad.1061803 PMID: 12756227; PubMed Central PMCID: PMCPMC196056.
13. Jung JW, Park SB, Lee SJ, Seo MS, Trosko JE, Kang KS. Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoSOne. 2011; 6(11):e28068. doi: 10.1371/journal.pone.0028068 PMID: 22132214; PubMed Central PMCID: PMCPMC3223228.
14. Han XY, Wei B, Fang JF, Zhang S, Zhang FC, Zhang HB, et al. Epithelial-mesenchymal transition associates with maintenance of stemness in spheroid-derived stem-like colon cancer cells. PLoS One. 2013; 8(9):e73341. doi: 10.1371/journal.pone.0073341 PMID: 24039918; PubMed Central PMCID: PMCPMC3767831.
15. Grosse-Wilde A, Fouquierd'Hérouël A, McIntosh E, Ertaylan G, Skupin A, Kuestner RE, et al. Stem-ness of the hybrid Epithelial/Mesenchymal State in Breast Cancer and Its Association with Poor Survival. PLoSOne. 2015; 10(5):e0126522. doi: 10.1371/journal.pone.0126522 PMID: 26020648; PubMed Central PMCID: PMCPMC4447403.
16. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119 (6):1420-8. doi: 10.1172/JCI39104 PMID: 19487818; PubMed Central PMCID: PMCPMC2689101.
17. Abell AN, Johnson GL. Implications of Mesenchymal Cells in Cancer Stem Cell Populations: Relevance to EMT. CurrPathobiol Rep. 2014; 2(1):21-6. doi: 10.1007/s40139-013-0034-7 PMID: 25530923; PubMed Central PMCID: PMCPMC4266994.
18. Hollestelle A, Peeters JK, Smid M, Timmermans M, Verhoog LC, Westenend PJ, et al. Loss of E-cad-herin is not a necessity for epithelial to mesenchymal transition in human breast cancer. Breast Cancer Res Treat. 2013; 138(1):47-57. doi: 10.1007/s10549-013-2415-3 PMID: 23338761.
19. Manuel Iglesias J, Beloqui I, Garcia-Garcia F, Leis O, Vazquez-Martin A, Eguiara A, et al. Mammo-sphere formation in breast carcinoma cell lines depends upon expression of E-cadherin. PLoS One. 2013; 8(10):e77281. doi: 10.1371/journal.pone.0077281 PMID: 24124614; PubMed Central PMCID: PMCPMC3790762.
20. Gheldof A, Berx G. Cadherins and epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci. 2013; 116:317-36. doi: 10.1016/B978-0-12-394311-8.00014-5 PMID: 23481201.
21. Chen A, Beetham H, Black MA, Priya R, Telford BJ, Guest J, et al. E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. BMC Cancer. 2014; 14:552. doi: 10.1186/1471-2407-14-552 PMID: 25079037; PubMed Central PMCID: PMCPMC4131020.
22. Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 2011; 13(3):R59. doi: 10.1186/bcr2896 PMID: 21663619; PubMed Central PMCID: PMCPMC3218948.
23. Miyamoto Y, Sakane F, Hashimoto K. N-cadherin-based adherens junction regulates the maintenance, proliferation, and differentiation of neural progenitor cells during development. Cell Adh Migr. 2015; 9 (3):183-92. doi: 10.1080/19336918.2015.1005466 PMID: 25869655.
24. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011; 68(18):3033-46. doi: 10.1007/s00018-011-0735-1 PMID: 21637948; PubMed Central PMCID: PMCPMC3162105.
25. Di Bella G, Mascia F, Gualano L, Di Bella L. Melatonin anticancer effects: review. Int J Mol Sci. 2013; 14(2):2410-30. doi: 10.3390/ijms14022410 PMID: 23348932; PubMed Central PMCID: PMCPMC3587994.
26. Jardim-Perassi BV, Arbab AS, Ferreira LC, Borin TF, Varma NR, Iskander AS, et al. Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. PLoSOne. 2014; 9(1):e85311. doi: 10.1371/journal.pone.0085311 PMID: 24416386; PubMed Central PMCID: PMCPMC3887041.
27. Kelleher FC, Rao A, Maguire A. Circadian molecular clocks and cancer. Cancer Lett. 2014; 342(1):9-18. doi: 10.1016/j.canlet.2013.09.040 PMID: 24099911.
28. Di Bella G, Mascia F, Colori B. The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature. Neuro Endocrinol Lett. 2013; 34 (6):523-8. PMID: 24378460.
29. Lopes JR, Maschio LB, Jardim-Perassi BV, Moschetta MG, Ferreira LC, Martins GR, et al. Evaluation of melatonin treatment in primary culture of canine mammary tumors. Oncol Rep. 2015; 33(1):311-9. doi: 10.3892/or.2014.3596 PMID: 25384569.
30. Hill SM, Belancio VP, Dauchy RT, Xiang S, Brimer S, Mao L, et al. Melatonin: an inhibitor of breast cancer. Endocr Relat Cancer. 2015; 22(3):R183-R204. doi: 10.1530/ERC-15-0030 PMID: 25876649; PubMed Central PMCID: PMCPMC4457700.
31. Wang Y, Zhou BP. Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chin J Cancer. 2011; 30(9):603-11. doi: 10.5732/cjc.011.10226 PMID: 21880181; PubMed Central PMCID: PMCPMC3702729.
32. Zhao H, Wu QQ, Cao LF, Qing HY, Zhang C, Chen YH, et al. Melatonin inhibits endoplasmic reticulum stress and epithelial-mesenchymal transition during bleomycin-induced pulmonary fibrosis in mice. PLoSOne. 2014; 9(5):e97266. doi: 10.1371/journal.pone.0097266 PMID: 24818755; PubMed Central PMCID: PMCPMC4018327.
33. Mao L, Dauchy RT, Blask DE, Slakey LM, Xiang S, Yuan L, et al. Circadian gating of epithelial-to-mesenchymal transition in breast cancer cells via melatonin-regulation of GSK3ß. Mol Endocrinol. 2012; 26 (11):1808-20. doi: 10.1210/me.2012-1071 PMID: 23002080; PubMed Central PMCID: PMCPMC3487627.
34. Martín V, Sanchez-Sanchez AM, Puente-Moncada N, Gomez-Lobo M, Alvarez-Vega MA, Antolín I, et al. Involvement of autophagy in melatonin-induced cytotoxicity in glioma-initiating cells. J Pineal Res. 2014; 57(3):308-16. doi: 10.1111/jpi.12170 PMID: 25163989.
35. Kannen V, Marini T, Zanette DL, Frajacomo FT, Silva GE, Silva WA, et al. The melatonin action on stro mal stem cells within pericryptal area in colon cancer model under constant light. Biochem Biophys Res Commun. 2011; 405(4):593-8. doi: 10.1016/j.bbrc.2011.01.074 PMID: 21266165.
36. Zhao J, Dong D, Sun L, Zhang G. Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer. IntBraz J Urol. 2014; 40(2):179-89. PMID: 24856504. doi: 10.1590/S1677-5538.IBJU.2014.02.07
37. Ferletta M, Grawé J, Hellmén E. Canine mammary tumors contain cancer stem-like cells and form spheroids with an embryonic stem cell signature. Int J DevBiol. 2011; 55(7-9):791-9. doi: 10.1387/ijdb.113363mf PMID: 22161835.
38. Qu Y, Han B, Yu Y, Yao W, Bose S, Karlan BY, et al. Evaluation of MCF10A as a Reliable Model for Normal Human Mammary Epithelial Cells. PLoSOne. 2015; 10(7):e0131285. doi: 10.1371/journal. pone.0131285 PMID: 26147507; PubMed Central PMCID: PMCPMC4493126.
39. Shaw FL, Harrison H, Spence K, Ablett MP, Simöes BM, Farnie G, et al. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J Mammary Gland Biol Neoplasia. 2012; 17(2):111-7. doi: 10.1007/s10911-012-9255-3 PMID: 22665270.
40. Jardim-Perassi BV, Lourenco MR, Doho GM, Grigolo IH, Gelaleti GB, Ferreira LC, et al. Melatonin Regulates Angiogenic Factors Under Hypoxia in Breast Cancer Cell Lines. Anticancer Agents MedChem. 2015. PMID: 25963143.
41. Borin TF, Arbab AS, Gelaleti GB, Ferreira LC, Moschetta MG, Jardim-Perassi BV, et al. Melatonin decreases breast cancer metastasis by modulating ROCK-1 expression. J Pineal Res. 2015. doi: 10.1111/jpi.12270 PMID: 26292662.
42. Dai M, Cui P, Yu M, Han J, Li H, Xiu R. Melatonin modulates the expression of VEGFand HIF-1 alpha induced by CoCl2in cultured cancer cells. J Pineal Res. 2008; 44(2):121-6. doi: 10.1111/j.1600-079X. 2007.00498.x PMID: 18289162.
43. Park SY, Jang WJ, Yi EY, Jang JY, Jung Y, Jeong JW, et al. Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia. J Pineal Res. 2010; 48(2):178-84. PMID: 20449875.
44. Alvarez-García V, González A, Alonso-González C, Martínez-Campa C, Cos S. Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. J Pineal Res. 2012; 52 (3):282-90. doi: 10.1111/j.1600-079X.2011.00940.x PMID: 22151118.
45. Carbajo-Pescador S, Ordoñez R, Benet M, Jover R, García-Palomo A, Mauriz JL, et al. Inhibition of VEGF expression through blockade of Hif1 a and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer. 2013; 109(1):83-91. doi: 10.1038/bjc.2013.285 PMID: 23756865; PubMed Central PMCID: PMCPMC3708553.
46. Cui P, Yu M, Peng X, Dong L, Yang Z. Melatonin prevents human pancreatic carcinoma cell PANC-1-induced human umbilical vein endothelial cell proliferation and migration by inhibiting vascular endothelial growth factor expression. J Pineal Res. 2012; 52(2):236-43. doi: 10.1111/j.1600-079X.2011.00933. x PMID: 21913973.
47. González A, Alvarez-García V, Martínez-Campa C, Alonso-González C, Cos S. Melatonin promotes differentiation of 3T3-L1 fibroblasts. J Pineal Res. 2012; 52(1):12-20. doi: 10.1111/j.1600-079X.2011. 00911.x PMID: 21718362.
48. Uva P, Aurisicchio L, Watters J, Loboda A, Kulkarni A, Castle J, et al. Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics. 2009; 10:135. doi: 10.1186/1471-2164-10-135 PMID: 19327144; PubMed Central PMCID: PMCPMC2670324.
49. Barbieri F, Thellung S, Ratto A, Carra E, Marini V, Fucile C, et al. In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: trans-lational implications for human tumors. BMC Cancer. 2015; 15:228. doi: 10.1186/s12885-015-1235-8 PMID: 25884842; PubMed Central PMCID: PMCPMC4397725.
50. Torres CG, Olivares A, Stoore C. Simvastatin exhibits antiproliferative effects on spheres derived from canine mammary carcinoma cells. Oncol Rep. 2015; 33(5):2235-44. doi: 10.3892/or.2015.3850 PMID: 25778435.
51. Magalhäes GM, Terra EM, de Oliveira Vasconcelos R, de Barros Bandarra M, Moreira PR, Rosolem MC, et al. Immunodetection of cells with a CD44+/CD24-phenotype in canine mammary neoplasms. BMC Vet Res. 2013; 9:205. doi: 10.1186/1746-6148-9-205 PMID: 24119896; PubMed Central PMCID: PMCPMC3852738.
52. Owens TW, Naylor MJ. Breast cancer stem cells. Front Physiol. 2013; 4:225. doi: 10.3389/fphys.2013. 00225 PMID: 23986719; PubMed Central PMCID: PMCPMC3753536.
53. Cocola C, Anastasi P, Astigiano S, Piscitelli E, Pelucchi P, Vilardo L, et al. Isolation of canine mammary cells with stem cell properties and tumour-initiating potential. Reprod Domest Anim. 2009; 44 Suppl 2:214-7. doi: 10.1111/j.1439-0531.2009.01413.x PMID: 19754572.
54. Michishita M, Akiyoshi R, Suemizu H, Nakagawa T, Sasaki N, Takemitsu H, et al. Aldehyde dehydrogenase activity in cancer stem cells from canine mammary carcinoma cell lines. Vet J. 2012; 193(2):508-13. doi: 10.1016/j.tvjl.2012.01.006 PMID: 22326935.
55. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. doi: 10.1016/j.cell.2008. 03.027 PMID: 18485877; PubMed Central PMCID: PMCPMC2728032.
56. Gerrard L, Zhao D, Clark AJ, Cui W. Stably transfected human embryonic stem cell clones express OCT4-specific green fluorescent protein and maintain self-renewal and pluripotency. Stem Cells. 2005; 23(1):124-33. doi: 10.1634/stemcells.2004-0102 PMID: 15625129.
57. Dick JE. Stem cell concepts renew cancer research. Blood. 2008; 112(13):4793-807. doi: 10.1182/blood-2008-08-077941 PMID: 19064739.
58. Linn DE, Yang X, Sun F, Xie Y, Chen H, Jiang R, et al. A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells. Genes Cancer. 2010; 1(9):908-16. doi: 10.1177/1947601910388271 PMID: 21779471; PubMed Central PMCID: PMCPMC3092260.
59. Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 2009; 16(12):3488-98. doi: 10.1245/s10434-009-0617-z PMID: 19657699.
60. Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 2010; 70(24):10433-44. doi: 10.1158/0008-5472. CAN-10-2638 PMID: 21159654.
61. Guo Y, Liu S, Wang P, Zhao S, Wang F, Bing L, et al. Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology. 2011; 59(4):763-75. doi: 10.1111/j.1365-2559.2011.03993.x PMID: 22014056.
62. Pang LY, Cervantes-Arias A, Else RW, Argyle DJ. Canine Mammary Cancer Stem Cells are Radio-and Chemo-Resistant and Exhibit an Epithelial-Mesenchymal Transition Phenotype. Cancers (Basel). 2011; 3(2):1744-62. doi: 10.3390/cancers3021744 PMID: 24212780; PubMed Central PMCID: PMCPMC3757388.
63. Yoo YM, Jung EM, Choi KC, Jeung EB. Effect of melatonin on mRNA expressions of transcription factors in murine embryonic stem cells. Brain Res. 2011; 1385:1-7. doi: 10.1016/j.brainres.2011.02.047 PMID: 21349252.
64. Gao S, Wang ZL, Di KQ, Chang G, Tao L, An L, et al. Melatonin improves the reprogramming efficiency of murine-induced pluripotent stem cells using a secondary inducible system. J Pineal Res. 2013; 55 (1):31-9. doi: 10.1111/jpi.12047 PMID: 23506542.
65. Yu Z, Sun M, Jin F, Xiao Q, He M, Wu H, et al. Combined expression of ezrin and E-cadherin is associated with lymph node metastasis and poor prognosis in breast cancer. Oncol Rep. 2015; 34(1):165-74. doi: 10.3892/or.2015.3967 PMID: 25955302.
66. Zhai X, Zhu H, Wang W, Zhang S, Zhang Y, Mao G. Abnormal expression of EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with clinicopathological features and prognosis in HCC. Med Oncol. 2014; 31(6):970. doi: 10.1007/s12032-014-0970-z PMID: 24781336.
67. Yan X, Yan L, Liu S, Shan Z, Tian Y, Jin Z. N-cadherin, a novel prognostic biomarker, drives malignant progression of colorectal cancer. Mol Med Rep. 2015; 12(2):2999-3006. doi: 10.3892/mmr.2015.3687 PMID: 25936636.
68. Cos S, Fernández R, Güézmes A, Sánchez-Barceló EJ. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res. 1998; 58(19):4383-90. PMID: 9766668.
69. Ma C, Li LX, Zhang Y, Xiang C, Ma T, Ma ZQ, et al. Protective and sensitive effects of melatonin combined with adriamycin on ER+ (estrogen receptor) breast cancer. Eur J Gynaecol Oncol. 2015; 36 (2):197-202. PMID: 26050360.
70. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol. 2004; 6(10):931-40. doi: 10.1038/ncb1173 PMID: 15448698.
71. Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, et al. Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res. 2003; 63(10):2658-64. PMID: 12750294.
72. Howard S, Deroo T, Fujita Y, Itasaki N. A positive role of cadherin in Wnt/ß-catenin signalling during epithelial-mesenchymal transition. PLoS One. 2011; 6(8):e23899. doi: 10.1371/journal.pone.0023899 PMID: 21909376; PubMed Central PMCID: PMCPMC3166074.
73. Sainz RM, Mayo JC, Rodriguez C, Tan DX, Lopez-Burillo S, Reiter RJ. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci. 2003; 60(7):1407-26. doi: 10.1007/s00018-003-2319-1 PMID: 12943228.
74. Zhang Y, Liu Q, Wang F, Ling EA, Liu S, Wang L, et al. Melatonin antagonizes hypoxia-mediated glioblastoma cell migration and invasion via inhibition of HIF-1 a. J Pineal Res. 2013; 55(2):121-30. doi: 10.1111/jpi.12052 PMID: 23551342.
75. Ordoñez R, Carbajo-Pescador S, Prieto-Dominguez N, García-Palomo A, González-Gallego J, Mauriz JL. Inhibition of matrix metalloproteinase-9 and nuclear factor kappa B contribute to melatonin prevention of motility and invasiveness in HepG2 liver cancer cells. J Pineal Res. 2014; 56(1):20-30. doi: 10.1111/jpi.12092 PMID: 24117795.
76. Zhou Q, Gui S, Wang Y. Melatonin inhibits the migration of human lung adenocarcinoma A549 cell lines involving JNK/MAPK pathway. PLoSOne. 2014; 9(7):e101132. doi: 10.1371/journal.pone. 0101132 PMID: 24992189; PubMed Central PMCID: PMCPMC4084631.
77. Ortíz-López L, Morales-Mulia S, Ramírez-Rodríguez G, Benítez-King G. ROCK-regulated cytoskeletal dynamics participate in the inhibitory effect of melatonin on cancer cell migration. J Pineal Res. 2009; 46(1):15-21. doi: 10.1111/j.1600-079X.2008.00600.x PMID: 18482340.
78. Mao L, Yuan L, Slakey LM, Jones FE, Burow ME, Hill SM. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res. 2010; 12(6):R107. doi: 10.1186/bcr2794 PMID: 21167057; PubMed Central PMCID: PMCPMC3046452.